SYH2070 injection for homozygous familial high cholesterol
Part of Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study tests a new injectable medication (SYH2070) designed to lower cholesterol in people with homozygous familial hypercholesterolemia—a genetic condition that causes extremely high cholesterol levels despite treatment. The goal is to see if this drug safely reduces cholesterol better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and weigh at least 40 kg (about 88 lbs)
- You have a genetic diagnosis or clear clinical diagnosis of homozygous familial hypercholesterolemia (the severe inherited form, not the milder heterozygous form)
- Your cholesterol (LDL-C) remains elevated even with stable cholesterol-lowering medications
- You have been on the same cholesterol medications for a set period and can stay on them throughout the study
- You are willing to use effective birth control if you can have children, and are not pregnant or breastfeeding
- You have not received certain other experimental cholesterol treatments (like mipomersen, bepatide, or gene editing) within specific timeframes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the long-term safety and effectiveness of the drug SHR-1918. It is for people with homozygous familial hypercholesterolemia who have already benefited from this drug in a previous study.
This study tests a new injection called SYH2053 for people with HeFH, a genetic condition that causes very high cholesterol. It looks at whether the injection can safely lower LDL cholesterol when added to standard statin therapy.
This trial tests an investigational injection called SYH2070 to lower cholesterol and triglycerides in people who are already on a stable statin therapy. It may be a new option for those with mixed hyperlipidemia who need additional lipid control.
This study tests a new injection called SYH2070 for people with high triglycerides and high LDL cholesterol. The goal is to see if a single dose is safe and how the body processes the medication. It is for people who have not been on cholesterol-lowering drugs recently.
This trial tests a new medication called SYH2053 for people with high cholesterol or mixed high cholesterol and triglycerides. If you have high LDL cholesterol and are not taking strong cholesterol medicines, you may be able to join. The study will see if this drug is safe and works well.
This trial tests a new investigational medicine (SYH2053) for people with high cholesterol or mixed hyperlipidemia who are already on cholesterol-lowering therapy but still have high levels of 'bad cholesterol' (LDL-C). The goal is to see if this add-on treatment can help lower cholesterol further and reduce heart disease risk.
Hear when a new Diagnosed With HoFH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.